• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?在新辅助全身治疗后，HER2阴性残留乳腺癌患者改用曲妥珠单抗-美坦新偶联物（T-DM1）是否仍合理？
Breast. 2025 Jun;81:103885. doi: 10.1016/j.breast.2025.103885. Epub 2025 Jan 21.
2
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.曲妥珠单抗-美坦新偶联物用于治疗残留浸润性 HER2 阳性乳腺癌。
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
3
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
4
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.在 MARIANNE 研究中，曲妥珠单抗-美坦新偶联物±帕妥珠单抗对比曲妥珠单抗联合紫杉烷类用于 HER2 阳性晚期乳腺癌的 III 期研究中，肿瘤标志物与疗效的关系。
BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0.
5
Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.辅助曲妥珠单抗-美坦新偶联物对转移性乳腺癌发病率的人群影响：新辅助治疗后残留疾病的 HER2 阳性早期乳腺癌女性的流行病学预测模型。
Breast Cancer. 2024 Jan;31(1):84-95. doi: 10.1007/s12282-023-01514-w. Epub 2023 Nov 1.
6
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.曲妥珠单抗恩美曲妥珠单抗治疗残留HER2阳性乳腺癌的生存情况
N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070.
7
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.人表皮生长因子受体 2（HER2）阳性早期乳腺癌（BC）的降级策略：德国西部研究组辅助动态标志物调整个体化治疗试验的最终分析，该试验优化了早期 BC 的 HER2 和激素受体阳性患者的风险评估和治疗反应预测，随机 II 期试验比较了曲妥珠单抗恩坦辛联合或不联合内分泌治疗（ET）与曲妥珠单抗加 ET 的新辅助治疗 12 周的疗效、安全性和预测标志物。
J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.
8
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy.对于新辅助治疗后HER2阴性残留浸润性乳腺癌患者，改用ado曲妥珠单抗-emtansine仍然合理。
Breast. 2025 Jun;81:104450. doi: 10.1016/j.breast.2025.104450. Epub 2025 Mar 20.
9
Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.帕妥珠单抗和 ado-trastuzumab emtansine 对美国局部晚期、炎性或早期 HER2 阳性乳腺癌女性患者复发累积避免的影响。
Adv Ther. 2023 Sep;40(9):3857-3874. doi: 10.1007/s12325-023-02554-6. Epub 2023 Jun 26.
10
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).曲妥珠单抗恩美曲妥珠单抗（T-DM1）+帕妥珠单抗（P）联合多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗（TCbHP）新辅助治疗人表皮生长因子受体 2（HER2）阳性原发性乳腺癌的长期结果：随机 2 期 JBCRG20 研究（Neo-peaks）的结果。
Breast Cancer Res Treat. 2024 Aug;207(1):33-48. doi: 10.1007/s10549-024-07333-7. Epub 2024 May 20.

引用本文的文献

1
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy.对于新辅助治疗后HER2阴性残留浸润性乳腺癌患者，改用ado曲妥珠单抗-emtansine仍然合理。
Breast. 2025 Jun;81:104450. doi: 10.1016/j.breast.2025.104450. Epub 2025 Mar 20.

本文引用的文献

1
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.乳腺癌新辅助治疗前后预处理活检和残留疾病中 HER2 表达的演变。
Eur J Cancer. 2024 Apr;201:113920. doi: 10.1016/j.ejca.2024.113920. Epub 2024 Feb 10.
2
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.早期乳腺癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13.
3
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature.新辅助治疗后切除标本中 HER2 蛋白表达减少的预后影响：单中心经验和文献复习。
Breast. 2023 Dec;72:103586. doi: 10.1016/j.breast.2023.103586. Epub 2023 Oct 3.
4
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.辅助 T-DM1 与曲妥珠单抗治疗曲妥珠单抗新辅助治疗后残留浸润性疾病的 HER2 阳性乳腺癌患者：来自 KATHERINE 的亚组分析。
Ann Oncol. 2021 Aug;32(8):1005-1014. doi: 10.1016/j.annonc.2021.04.011. Epub 2021 Apr 28.
5
Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer.HER2阳性乳腺癌新辅助治疗后HER2缺失与疾病预后
Am J Transl Res. 2019 Sep 15;11(9):6110-6116. eCollection 2019.
6
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.曲妥珠单抗-美坦新偶联物用于治疗残留浸润性 HER2 阳性乳腺癌。
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
7
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.曲妥珠单抗治疗后 HER2 阳性乳腺癌患者的 HER2 状态丢失及其预后
Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7.

在新辅助全身治疗后，HER2阴性残留乳腺癌患者改用曲妥珠单抗-美坦新偶联物（T-DM1）是否仍合理？

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?

作者信息

Tjalma Wiebren, Teuwen Laure-Anne, Altintas Sevilay, Papadimitriou Konstantinos

机构信息

Multidisciplinary Breast Clinic, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium; Faculty of Medicine, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.

Multidisciplinary Breast Clinic, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium; Faculty of Medicine, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.

出版信息

Breast. 2025 Jun;81:103885. doi: 10.1016/j.breast.2025.103885. Epub 2025 Jan 21.

DOI:10.1016/j.breast.2025.103885
PMID:39890556
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12144929/
Abstract

The standard of care for HER2-positive and hormone receptor-positive breast cancer patients who receive neoadjuvant chemotherapy (NACT) combined with trastuzumab, with or without pertuzumab, is to continue with adjuvant T-DM1 in cases of an incomplete response according to KATHERINE trial results. However, the optimal management for patients with residual disease with loss of HER2 expression is not widely studied. Loss of HER2 expression after NACT with anti HER2 is a rarer event with questionable value both as a predictive prognostic marker.

摘要

对于接受新辅助化疗（NACT）联合曲妥珠单抗（无论是否联合帕妥珠单抗）的HER2阳性和激素受体阳性乳腺癌患者，根据KATHERINE试验结果，治疗标准是在反应不完全的情况下继续使用辅助性曲妥珠单抗偶联物（T-DM1）。然而，对于HER2表达缺失的残留病患者的最佳管理方法尚未得到广泛研究。使用抗HER2药物进行新辅助化疗后HER2表达缺失是一种较罕见的情况，作为预测性预后标志物，其价值存疑。